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Abstract 
Bacterial resistance to antibiotics is a global public 
health concern. New treatments are needed to combat 
resistant strains, among which phage therapy is a 
promising option. Probably the main advantages of 
phage therapy are its high specificity as well as rapid 
viral adaptability, which in principle allows using phage 
evolution to overcome resistance. Here, we have 
performed serial coevolution passages between 
Escherichia coli and its phage T7 to investigate the 
ability of coevolved phages to reduce the emergence of 
resistances. We find that the initial bacterial population 
is less likely to undergo resistance when challenged 
with experimentally coevolved phages than when 
challenged with the wild-type phage. Hence, our 
findings suggest that coevolved phage preparations 
could be used to increase the efficacy of phage therapy.  
Keywords: Bacterial resistance; Phage therapy; 
Phage-bacteria 
1. Introduction 
The emergence of multi-drug-resistant bacteria calls for 
novel therapeutic strategies. In this context, 
bacteriophages (phages), whose therapeutic use was 
long-ago suggested, are being now reconsidered. Phages 
are natural parasites of bacteria and the most abundant 
entity in the biosphere, making them an attractive tool 
for fighting against bacterial pathogens [1-4]. One 
important difference between antibiotics and phages is 
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that many antibiotics cover a broad spectrum of 
bacteria, whereas phage are typically species- or genus-
specific. In acute infections, specificity can be 
problematic because treatment often precedes diagnosis, 
although phage cocktails can be used to broaden host 
range and improve effectiveness. Yet, specificity is 
clearly advantageous for treating long-term infections, 
since side-effects such as damage to the physiological 
microbiota are avoided [5]. On the other hand, long-
term treatments are particularly prone to the emergence 
of resistances, although resistance also emerges among 
acute disease-causing bacteria at the host population 
level [6]. Bacteria and their phages coevolve in nature, 
and understanding phage-bacteria evolutionary 
dynamics should help us design better phage therapy 
interventions [7]. 
 
The emergence of bacterial resistance against phages is 
in many cases rapid and frequent, but unlike antibiotics, 
phages can evolve resistance-breaking by spontaneous 
mutation and natural selection [4, 8, 9]. In addition, 
phage-resistant bacteria are generally costly, producing 
a drop in virulence in many cases. Generally, phages 
mutate faster than their hosts [10, 11], which provides 
them a clear evolutionary advantage. However, bacteria 
have evolved elaborate and flexible mechanisms to 
block infection. These mechanisms include point 
mutations in specific proteins like phage receptors, 
restriction-modification systems, and clustered regularly 
interspaced short palindromic repeats (CRISPR)-Cas 
adaptive immunity [8, 12]. In turn, phages have evolved 
specific genes to inactivate the CRISPR-Cas system, 
called anti-CRISPRs (Acrs), as expected under an 
evolutionary arms race [13-15]. Antagonistic phage-
bacteria coevolution can have multiple population-level 
implications [16, 17], including increased genetic 
diversity in both phage and bacteria [18], directional 
increases in host resistance and parasite infectivity [19], 
and negative frequency-dependent selection causing 
fluctuations in allele frequency [20, 21]. 
 
Promoting phage-bacteria coevolution in the laboratory 
may thus help us obtain phages capable of infecting a 
wider range of variants in the bacterial population and to 
overcome the emergence of resistances during 
treatment. Previous studies examined phage-bacteria 
coevolution mainly in chemostats and reported a variety 
of outcomes, including phage and host persistence, as 
well as full host resistance leading to phage extinction 
[16]. Here, we provide basic proof of concept for a 
coevolution approach to phage therapy using 
Escherichia coli and its phage T7 as model system. 
Previous work using this phage-bacteria system showed 
that the evolution of both resistance and resistance 
breaking are common [22]. E. coli is the most abundant 
commensal bacterium in the mammalian intestine and 
some strains are well-known pathogens [23]. Pathogenic 
strains have been reported worldwide, and their 
appearance is associated to the emergence of resistance. 
We chose bacteriophage T7, a double-stranded DNA 
phage, because it shows a rapid and highly lytic 
infection cycle, which is an interesting feature for phage 
therapy but also a convenient feature for basic studies. + 
viruses are the most abundant type of phage and, despite 
their lower mutation rates compared to RNA phages, 
they can also adapt efficiently under controlled 
laboratory conditions [24]. In addition, relatively large 
double-stranded DNA viruses are interesting from the 
therapeutic point of view because they can more easily 
incorporate transgenes aimed at improving treatment 
efficacy. We find that, after only ten serial transfers of 
coevolution with their host, the resulting coevolved 
phages improve their lytic activity and are superior to 
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2. Materials and Methods 
2.1 Bacterial strain, bacteriophage and culture 
conditions 
Escherichia coli C IJ1862 strain and bacteriophage T7 
were kindly provided by Prof. James J. Bull (University 
of Texas). General biology of the phage can be found 
elsewhere [25]. E. coli C IJ1862 was cultured in 
Lysogeny Broth (LB) medium at 37°C in an orbital 
shaker (250 rpm). A stock of IJ1862 was obtained by 
growing the bacterium to stationary phase and storage at 
-70°C in glycerol 20% (v/v). Serial dilutions from this 
stock were performed to isolate three independent 
colonies, which were used to initiate coevolution 
experiments. Isolated bacterial colonies were picked 
randomly and resuspended in 50 µL LB. Serial dilutions 
were prepared, plated onto LB plates and incubated until 
single colonies were observed to determine bacterial 
density of these colony-derived populations. In parallel, 
100 µL of IJ1862 were mixed with 100 µL of serial 
dilutions of phage T7 and poured onto dishes containing 
LB medium semi-solidified with soft agar (0.7%) and 
supplemented with 5 mM of CaCl2 to obtain isolated 
plaques. After 6 h of incubation at 37°C, three 
independent plaques were picked randomly, 
resuspended in 50 µL of LB, and stored at -70°C. These 
three plaques were used to initiate the coevolution 
experiments.  
 
2.2 Coevolution passages 
Three independent coevolution lines (C1-C3) were 
initiated, each derived from a single plaque-derived 
virus and a single colony-derived bacterial culture as 
detailed above. For each coevolution line, 10
5
 plaque 
forming units (PFU) of phage were used to inoculate 10
8
 
colony forming units (CFU) of IJ1862 cells at their 
exponential growth phase in liquid LB medium 
supplemented with 5 mM CaCl2. Infected cultures were 
incubated under agitation (650 rpm) at 37°C in a 
Thermomixer 24-tube shaker (Eppendorf). After 24 h, 
the culture was diluted 1:100 in fresh LB medium to 
initiate the next passage. Ten serial passages of 
coevolution were performed. After each passage, the 
viral titer was determined by plaque assay. For this, 
bacteria were first cleared by centrifugation (16, 000 × 
g, 1 min) and the supernatant was poured onto dishes 
containing the bacterium in soft agar. In addition, after 
each passage, optical density (OD600) was used to 
measure bacterial density (CFU/mL). A calibration 
curve between OD600 and bacterial density was made by 
performing serial dilutions, plating and colony counting. 
When bacterial density was below the sensitivity limit 
of OD600 measurements, colony counting was 
performed. 
 
2.3 Determination of bacterial lysis 
Coevolved and founder phages were assayed for their 
ability to lyse cells from the non-coevolved bacterial 
stock. To accomplish this aim, 10
8
 CFU from the 
founder bacterial culture were inoculated with 10
5
 PFU 
of each phage line (founder and coevolved phages) in 
liquid LB medium supplemented with 5 mM CaCl2 and 
incubated at 37°C and 600 rpm in a Varioskan LUX 
multimode microplate reader (Thermo Scientific) to 
determine bacterial density. Six independent technical 
replicates were done per line, and OD600 readings were 
obtained every 4 min for the first 2 h and every 15 min 
subsequently, for a total time of 100 h.  
 




 CFU of the non-coevolved bacterial 
stock with 10
7
 PFU of founder or coevolved phages and 
poured it onto LB plates solidified with soft agar 
(supplemented with 5 mM CaCl2). At this multiplicity of 
infection, we expected all bacteria to be lysed except 
resistant mutants, which should form isolated colonies 
capable of growing in presence of the phage. Plates 
were incubated at 37°C until candidate resistant 
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colonies were observed. Each assay was done in 
triplicate. Candidate colonies were picked and stored at 
-70°C in LB with glycerol 20% (v/v) for further testing. 
To test for resistance, candidate colonies were spotted 
onto LB with soft agar containing 10
7
 PFU of the 
relevant phage and incubated at 37°C to determine 
whether cells grew or were lysed. 
 
3. Results 
3.1 Phage-host coevolution 
Coevolution was initiated using three pairs of T7 
plaque-derived and E. coli colony-derived populations. 
For this, each colony was expanded in liquid culture and 
inoculated with phage derived from a single plaque, 
resulting in three coevolution lines (C1-C3). Infected 
cultures were maintained in agitation for 24 h and 
diluted 1:100 to initiate the next passage, up to ten serial 
passages during which the phage and the host could in 
principle coevolve. In all the coevolution lines, the 
bacterium and the phage coexisted (Figure 1). In line 
C1, a six-fold drop in bacterial density occurred during 
the first passage, leading to a low-density plateau. The 
first infection produced a high phage titer (10
10
 
PFU/mL) as determined by the plaque assay, but phage 
titer gradually decreased until reaching a plateau at 
passage 5 of around 10
6
 PFU/mL. This suggests that the 
phage exhausted the host population initially, resulting 
in low densities of both bacteria and phage, and that 
fully resistant bacteria did not evolve or had low fitness. 
In contrast, in line C2, the phage titer remained high 
throughout the 10 passages, whereas the bacterial 
density dropped initially, but then rebounded drastically 
in passage 3, suggesting the emergence of resistant 
bacteria in the population. Finally, line C3 showed a 
qualitatively similar pattern to C2, albeit bacterial 
density rebounded later, suggesting the emergence of 
resistant variants around passage 6. 
 
Figure 1: Viral titers and bacterial densities along coevolution passages. Viral titers (PFU/mL) are shown in solid 
lines, whereas dotted lines represent bacterial densities (CFU/mL). Pink: line C1; blue: line C2; red: line C3. 
 
3.2 Dynamics of bacterial regrowth following 
challenge with phage 
We compared the ability of the founder and coevolved 
phages to clear the initial bacterial population and, in 
particular, to prevent regrowth after initial lysis. For 
this, we challenged 10
8
 CFU of the non-coevolved 
bacteria with 10
5
 PFU of phages (founder and 
coevolved lines) in liquid medium and measured optical 
density in real time over 100 h of culture (Figure 2). Six 
replicate cultures were carried out for each condition. 
Bacterial growth was halted approximately 45 min after 
phage inoculation and lysis occurred within the first 90 
min in all cases. After lysis, bacterial density remained 
stably low for at least 5 h post inoculation (hpi). 
Cultures that were challenged with coevolved phages 
(C1-C3) showed lower log-density than those infected 
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with the founder phage, indicating more efficient lysis. 
Phages from line C1 showed the highest antibacterial 
efficacy, followed by C3 and C2 (t-tests: founder versus 
C1, P=0.0160; founder versus C2, P=0.0314; founder 
versus C3, P=0.0420). In most cases, this was followed 
by a slow and gradual phase of bacterial regrowth, 
which was first evident in cultures treated with founder 
phages and was maximally delayed for those treated 
with C1 phages, whereas C2 and C3 showed 
intermediate rebound times. In C3-treated cultures we 
observed a sharp increase in log-density around 20 
hours post inoculation (hpi) in one replicate, clearly 
showing the emergence of a high-fitness, phage-
resistant bacterial mutant. Removing this outlier, we 
found significantly lower log-densities at 50 hpi in 
cultures treated with each of the three coevolved phages 
compared to those treated with founder virus (t-tests: 
founder versus C1, P=0.0012; founder versus C2, 
P=0.0097; founder versus C3, P=0.0180). At the final 
time point (100 hpi), we found lower log-densities in 
cultures treated with C1 coevolved phages compared to 
those treated with the founder phage, but no differences 
were found for lines C2 and C3. 
 
 
Figure 2: Dynamics of bacterial regrowth following challenge with phage. (A) Optical density of cultures of the 
non-coevolved bacteria infected with founder or coevolved phages. Six experimental replicates were done for each 
condition. Cultures treated with the founder phage (black), C1 (pink), C2 (blue), or C3 (red) are shown; (B) Optical 
densities at specific time points (0, 5, 50 and 100 hours post inoculation). 
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3.3 Analysis of phage-resistant colonies and 
resistance breaking 
The above assays provided an overview of the increased 
ability of the coevolved phages to lyse bacteria and 
prevent regrowth, but did not provide information about 
the number of phage-resistant bacterial mutants 
emerged. For instance, a single high-fitness resistant 
mutant may repopulate the entire culture, as suggested 
by the outlier found in one replicate treated with C3 
phages. To achieve this goal, we inoculated 10
6
 CFU of 
the non-coevolved bacteria with 10
7
 PFU of the founder 
or coevolved phage in dishes overlaid with soft agar, 
which allowed us to visualize resistant colonies. In 
dishes inoculated with the founder phage, we found 
between 20 and 100 resistant colonies (resistance rate 




), whereas for C1-C3 
phages the number of resistant colonies was between 
zero and five (resistance rate ranging from 0 to 5 ×10
-7
). 
Whilst most colonies were remarkably small even after 
3 days of incubation, a few colonies showed sizes 
comparable to those observed in the absence of phage. 
This indicates that levels of resistance and/or the fitness 
costs of resistance were amply variable, as also 
suggested by the optical density measurements. We 
picked 26 colonies randomly from dishes infected with 
the founder phage and 15 (all) from dishes infected with 
C1, C2, or C3 and evaluated their resistance to each 
phage by spotting them onto phage-containing dishes in 
soft agar (Figure 3). All 15 colonies derived from 
coevolved-infected cultures were resistant to all phages 
(founder, C1, C2, and C3), whereas only 9/26 colonies 
derived from founder-infected cultures were resistant to 
all phages, revealing a significant association between 
the origin of the colony (pre-infected with founder 
versus coevolved phage) and its subsequent resistance 
status (Fisher exact test: P<0.001). This suggests, first, 
that C1-C3 populations contained phages capable of 
infecting E. coli variants that were resistant to the non-
coevolved phage. On the other hand, these results also 
suggest that some E. coli resistance mechanisms were 
efficient against all T7 phage variants. 
 
 
Figure 3: Analysis of phage-resistant colonies and resistance breaking. Resistance was tested by spotting each 
colony on each phage. Each column corresponds to an isolated colony from the indicated line, and each row 
corresponds to a phage line. Blue: bacterial growth. Red: lysis. 
 
4. Discussion 
Bacteria and viruses are excellent systems for studying 
basic evolutionary processes such as mutation, 
selection, and genetic drift in real time under controlled 
conditions, which in turn are important for 
understanding the emerge of resistances [26, 27]. 
Although phage therapy is an interesting alternative to 
classical antibiotics, it also faces the problem of 
bacterial resistance. Yet, as opposed to antibiotics, 
evolvability is an inherent property of phages. Here, we 
sought to explore the ability of phage to engage in a 
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short-term antagonistic coevolution process with its host 
under controlled laboratory conditions, and we tested 
whether the resulting coevolved phages could be a 
better choice than the wild-type phage in terms of lysis 
strength and/or delaying resistance. We found that in 3/3 
coevolution lines the phage did not go extinct, 
suggesting that coevolution is a robust and, hence, easy-
to-implement process. Providing proof of concept for 
the utility of coevolved phages, they delayed the timing 
of bacterial regrowth and produced fewer resistance 
colonies than an equivalent dose of wild-type non-
coevolved phage.  
 
In future work, it would be useful to sequence the 
coevolved populations of phages and bacteria to gain 
information about the mechanisms underlying this 
antagonistic coevolution. Sequencing should allow us to 
identify specific mutations responsible for resistance 
and resistance breaking, and to determine their 
abundance in natural populations and clinical isolates. 
For future applications, it may be required to identify 
resistance-breaking mutations in the phage genome and 
prepare phage cocktails of known composition that 
include these mutants, instead of using raw coevolved 
preparations. CRISPR-Cas loci are important drivers of 
phage-host antagonistic coevolution [28, 29]. The E. 
coli strain used here belongs to phylogenic group C, 
which contains two pairs of CRISPR loci, each 
associated with a different type of Cas genes [30]. Yet, 
there are other possible molecular determinants of 
antagonistic coevolution, such as loss of the receptor 
and use of alternative receptors by the phage [8, 31]. 
 
Finally, given their wide abundance and diversity, 
multiple candidate phages might be available to fight 
against a given bacterium, but we currently lack a 
general understanding on which type of phage should 
perform best. On one hand, RNA phages may be more 
evolvable than DNA phages because they mutate faster, 
but large DNA phages might display a larger number of 
alternative infection mechanisms owing to their higher 
genome complexity and, thus, may counteract resistance 
better. Comparative studies of the coevolutionary 
process of a given bacterial species with different 
phages may help illuminate this point. 
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